Clinical Trials Logo

IL-2 Induced Hypotension clinical trials

View clinical trials related to IL-2 Induced Hypotension.

Filter by:
  • None
  • Page 1

NCT ID: NCT00033956 Suspended - Clinical trials for IL-2 Induced Hypotension

Evaluation of M40403 for the Prevention of Dose Limiting Toxicities of High Dose IL-2

Start date: December 2001
Phase: Phase 1/Phase 2
Study type: Interventional

The clinical use of IL-2 is currently limited by development of dose-dependent hypotension (systolic blood pressure (SBP) < 90 mm Hg). The overall outcome is constant across sites with 20-50% of the patients requiring ICU management because of unresponsive hypotension and hyporeactivity (loss of response to vasoconstrictors). Because of the dose-limiting side effects, the duration of IL-2 dosing is frequently curtailed. Thus, hemodynamic toxicities have limited the usefulness of IL-2 therapy. M40403 has prevented both the hypotension and hyporeactivity associated with IL-2 treatment in preclinical studies. This trial will study the safety and efficacy of M40403 in the prevention or reduction of hypotension in patients receiving IL-2 therapy.